Osmotica Amends NDA for Arbaclofen ER to Treat MS Spasticity
Osmotica Pharmaceuticals has submitted an amended new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of arbaclofen extended release (ER) tablets for the treatment of spasticityĀ in people with multiple sclerosis (MS). Arbaclofen ER (brand name…